Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes

OVERVIEW

The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study was a one-year, community-based, multi-centre, randomised controlled trial assessing the degree to which a statin and/or omega-3 fatty acids reduce the estimated risk of coronary heart disease (CHD) in 1,000 people with Type 2 diabetes.

RESULTS

The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006

[Read More]

Principal investigator	Rury Holman Andrew Neil
Co-investigators	Andrew Farmer
Sponsor	Pfizer Ltd
Reference number	ISRCTN76737502

Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes

Contact us

OVERVIEW

RESULTS

AFORRD PUBLICATIONS

Economic evaluation of factorial trials: cost-utility analysis of the AFORRD 2x2x2 factorial trial of atorvastatin, omega-3 fish oil and action-planning

The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled trial

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial

AFORRD Conference Abstracts

LDL cholesterol levels alone do not adequately assess coronary heart disease risk in Type 2 diabetes [Diabetes UK Annual Professional Conference]

LDL Cholesterol Level Alone does not Assess Coronary Heart Disease Risk Adequately in Type 2 Diabetes [66th Scientific Session of the American Diabetes Association]

AFORRD: a multi-centre trial evaluating potential cardiovascular risk reduction in patients with type 2 diabetes randomised in a factorial design to atorvastatin and/or omega-3 polyunsaturated fatty acids [Diabetes UK Annual Professional Conference]